Despite beating analyst expectations, Takeda sustains a mid-stage defeat in a rare genetic disorder, leaving the fate of an investigational enzyme replacement therapy uncertain.
https://www.pharmalive.com/wp-content/uploads/2023/05/Takeda-building.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-07-28 09:14:252023-07-28 09:32:29Takeda likely to drop rare genetic disease candidate after Phase II fail
